← Leaderboards
Ellen Elizabeth Sparger
Tendel Therapies Inc.
$10,507,291
Attributed
$13,774,196
Total exposure
21
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,774,196 · 21
By mechanism
R01$6,675,517 · 5
R44$2,571,682 · 2
R21$1,327,747 · 4
P01$942,815 · 1
P51$806,371 · 6
R56$773,051 · 1
Top collaborators
- Peter A Barry10 shared
- Barbara L Shacklett5 shared
- Dennis J Hartigan-O'Connor2 shared
- Satya Dandekar1 shared
Others in their field
Top investigators on “Vector Vaccine”
- Lawrence Corey · Fred Hutchinson Cancer Center$446,547,761
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$239,426,049
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$142,420,923
- Peter B. Gilbert · Fred Hutchinson Cancer Center$124,587,333
- Louis J. Picker · Oregon Health And Science University$70,366,260
- David Heimbrook · Leidos Biomedical Research, Inc.$68,561,099
Research focus
Vector VaccineVaccinesMacaca MulattaCellsViralHiv-1InfectionVirusVaccine DevelopmentResponseAntigensImmunogenicityVectorTissuesViral VaccinesImmune ResponseAdjuvantNonhuman PrimateBaseImmunizationT-LymphocyteAttenuatedHiv VaccineInvestigation
Grant awards (39)
Optimizing SIV reservoir depletion by Tendel bsAb-98$999,991
R44 · FY2025 · AI · contact PI
Strategies for targeting T follicular helper cells to improve HIV Env vaccine immunogenicity and efficacy$942,815
P01 · FY2025 · AI · contact PI
GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine$571,691
R44 · FY2024 · AI · contact PI
Genetic adjuvants to elicit neutralizing antibodies against HIV$300,083
R43 · FY2024 · MH · contact PI
GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine$1,000,000
R44 · FY2023 · AI · contact PI
Genetic adjuvants to elicit neutralizing antibodies against HIV$300,930
R43 · FY2023 · MH · contact PI
CMV-vectored Vaccine Approaches to Induce Protective Antibodies to HIV-1 Env$186,899
R21 · FY2018 · AI
CMV-vectored Vaccine Approaches to Induce Protective Antibodies to HIV-1 Env$232,677
R21 · FY2017 · AI
Impact of chronic viral infections and altered microbiota on HIV vaccine efficacy$773,051
R56 · FY2015 · AI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$548,792
R01 · FY2015 · DE · contact PI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$645,317
R01 · FY2014 · DE · contact PI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$613,281
R01 · FY2013 · DE · contact PI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$616,708
R01 · FY2012 · DE · contact PI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$623,184
R01 · FY2011 · DE · contact PI
Development and Immunogenicity of Attenuated RhCMVdelta10 Vaccine Vectors$189,857
R21 · FY2011 · AI · contact PI
Development and Immunogenicity of Attenuated RhCMVdelta10 Vaccine Vectors$229,586
R21 · FY2010 · AI · contact PI
HIGHLY ATTENUATED SIV VIF DNA VACCINES$146,579
P51 · FY2009 · RR · contact PI
HIGHLY ATTENUATED SIV VIF DNA VACCINES$168,995
P51 · FY2008 · RR · contact PI
Cellular Immune Responses Induced by SIVdelta-vif plus IL-15 DNA Vaccine$76,000
R03 · FY2008 · AI · contact PI
Feline Immunodeficiency Virus Orf-A A Model for HIV Vpr$281,609
R01 · FY2007 · AI · contact PI
SIV Deltavif Reservoirs in Vivo$184,490
R21 · FY2007 · AI · contact PI
HIGHLY ATTENUATED SIV VIF DNA VACCINES$181,569
P51 · FY2007 · RR · contact PI
Feline Immunodeficiency Virus Orf-A A Model for HIV Vpr$290,021
R01 · FY2006 · AI · contact PI
HIGHLY ATTENUATED SIV VIF DNA VACCINES$117,515
P51 · FY2006 · RR · contact PI
SIV Deltavif Reservoirs in Vivo$113,625
R21 · FY2006 · AI · contact PI
Feline Immunodeficiency Virus Orf-A A Model for HIV Vpr$297,000
R01 · FY2005 · AI
HIGHLY ATTENUATED SIV VIF DNA VACCINES$155,250
P51 · FY2005 · RR
FIVDELTAVIF DNA Vaccines with Cytokine Adjuvants$297,000
R01 · FY2004 · AI
Feline Immunodeficiency Virus Orf-A a Model for HIV Vpr$297,000
R01 · FY2004 · AI
SIV delta vif DNA Vaccines with Cytokine Adjuvants$259,875
R01 · FY2004 · AI
SIV delta vif DNA Vaccines with Cytokine Adjuvants$334,578
R01 · FY2003 · AI
FIVDELTAVIF DNA Vaccines with Cytokine Adjuvants$297,000
R01 · FY2003 · AI
HIGHLY ATTENUATED SIV VIF DNA VACCINES$36,463
P51 · FY2003 · RR
FIVDELTAVIF DNA Vaccines with Cytokine Adjuvants$282,150
R01 · FY2002 · AI
FIVDELTAVIF DNA Vaccines with Cytokine Adjuvants$282,150
R01 · FY2001 · AI
HIGHLY ATTENUATED SIV VIF DNA VACCINES$257,250
R01 · FY2001 · AI
HIGHLY ATTENUATED SIV VIF DNA VACCINES$257,031
R01 · FY2000 · AI
INFECTION AND IMMUNITY WITH FIV MUTANT PROVIRUSES$195,571
R01 · FY2000 · AI
REGULATED FIV VECTORS FOR VACCINATION$190,613
R21 · FY2000 · AI